88 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
6 Mar 24
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
7:05am
received R&D tax credits from the UK government in January 2024 of $30.8m
Financial Results for the three months and year ended December 31, 2023
Cash … income for the collaboration being recognized as revenue in March 2023.
Research and development (R&D) expenses: R&D expenses for the three months
8-K
EX-99.1
3wy686ly
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K/A
EX-99.3
jsqakapstyrvf4xukpsm
10 Aug 23
Financial Statements and Exhibits
4:05pm
8-K
EX-99.1
w5hg5lkp2xim2dhj
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
881nulj79jcgwt
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
r21iwqbth0n vkria
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
ngsof8epqz96exdppd1
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
8-K
EX-10.1
dou7 buuiihhc
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
S-4
8rzxmucm dkx
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-99.1
026y4o3p9kn mq
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am